To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

The offer may show employers how hard drug manufacturers will compete based on price, in at least some situations.

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...

These medications are not FDA-approved, meaning they do not undergo the rigorous testing for safety, effectiveness, and ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), ...